Novartis
NEWS
Amgen and Novartis scored a big win in the migraine market late Thursday when the U.S. Food and Drug Administration approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.
Basel, Switzerland-based Novartis announced that between the ASCO meeting and the 23rd Annual Congress of the European Hematology Association (EHA) meeting being held June 14 to 17 in Stockholm, Sweden, it will be presenting 84 abstracts.
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
The first Novartis executive has fallen in the wake of the $1.2 million payment to President Donald Trump’s attorney for consulting work.
The U.S. Food and Drug Administration (FDA) approved Pfizer’s Retacrit (epoetin alfa-epbx), a biosimilar to Amgen’s Epogen/Procrit (epoetin alfa). The drugs treat anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in HIV patients.
Members of the U.S. Senate are not done with Novartis regarding payment to Trump attorney.
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
Europe began approving biosimilars in 2006. The U.S. has lagged behind, only starting to approve these copycat drugs in 2015. However, of the nine biosimilars approved in the U.S., only three are actually on the market because of barriers thrown up by the biopharma industry.
Novartis paid far more than $400,000 to President Donald Trump’s lawyer Michael Cohen -- $800,000 more, the company revealed in a statement issued late Wednesday.
JOBS
IN THE PRESS